A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas

Inclusion criteria:

• Signed and dated informed consent form (ICF)2/main ICF for all patients describingthe study in accordance with International Council on Harmonisation Good ClinicalPractice (ICH-GCP) and local legislation prior to any trial-specific procedures,sampling, or analyses.

• Patient must be ≥18 years of age and at least at the legal age of consent incountries where it is greater than 18 years at the time of signature on the ICFs (ICF1/screening ICF and ICF2/main ICF).

• In US: Patients with a histologically or cytologically confirmed diagnosis ofcolorectal carcinoma (CRC), gastric carcinoma (GC), or pancreatic ductaladenocarcinoma (PDAC).

• In Europe: Patients with a histologically or cytologically confirmed diagnosis ofCRC.

• Patients with advanced, unresectable, and/or metastatic disease. Further inclusioncriteria apply.

Exclusion criteria:

• Patient with a history of a major surgery within 28 days prior to first dose of BI 765049 (major according to the Investigator's and/or Medical Monitor's assessment).

• Previous or concomitant malignancies other than the one treated in this trial withinthe last 5 years except:

• Effectively treated non-melanoma skin cancers

• Effectively treated carcinoma in situ of the cervix

• Effectively treated ductal carcinoma in situ

• Other effectively treated malignancy that is considered cured by localtreatment"

• Patient with known leptomeningeal disease or spinal cord compression due to disease.

• Patient requiring anticoagulant treatment which cannot be safely interrupted, ifmedically needed for a study procedure (e.g. biopsy) based on the opinion of theInvestigator.

Further exclusion criteria apply.